|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
33
|
|
pubmed:dateCreated |
2009-7-3
|
|
pubmed:abstractText |
The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1873-2518
|
|
pubmed:author |
pubmed-author:BiberfeldGunnelG,
pubmed-author:BraveAndreasA,
pubmed-author:CoxJosephineJ,
pubmed-author:EarlPatriciaP,
pubmed-author:GudmundsdotterLindviL,
pubmed-author:HejdemanBoB,
pubmed-author:MarovichMaryM,
pubmed-author:MossBernardB,
pubmed-author:NelsonMichaelM,
pubmed-author:NilssonCharlottaC,
pubmed-author:RobbMerlinM,
pubmed-author:SandströmEricE,
pubmed-author:WahrenBrittaB
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4468-74
|
|
pubmed:dateRevised |
2009-8-20
|
|
pubmed:meshHeading |
pubmed-meshheading:19450644-AIDS Vaccines,
pubmed-meshheading:19450644-Adult,
pubmed-meshheading:19450644-Age Factors,
pubmed-meshheading:19450644-Animals,
pubmed-meshheading:19450644-Antibodies, Viral,
pubmed-meshheading:19450644-Cell Line,
pubmed-meshheading:19450644-Cercopithecus aethiops,
pubmed-meshheading:19450644-Female,
pubmed-meshheading:19450644-HIV Antigens,
pubmed-meshheading:19450644-HIV Infections,
pubmed-meshheading:19450644-HIV-1,
pubmed-meshheading:19450644-Humans,
pubmed-meshheading:19450644-Immunity, Cellular,
pubmed-meshheading:19450644-Immunization, Secondary,
pubmed-meshheading:19450644-Male,
pubmed-meshheading:19450644-Middle Aged,
pubmed-meshheading:19450644-Neutralization Tests,
pubmed-meshheading:19450644-Vaccines, DNA,
pubmed-meshheading:19450644-Vaccines, Synthetic,
pubmed-meshheading:19450644-Vaccinia virus,
pubmed-meshheading:19450644-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.
|
|
pubmed:affiliation |
Karolinska Institutet and Swedish Institute for Infectious Disease Control, Stockholm, Sweden. L.gudmundsdotter@smi.se
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
